Puma reports decline in first-quarter profit margin
Puma's sales of 2.076 billion euros (USD 2.35 billion) were slightly better than analysts' forecast of 2.041 billion euros, up by 0.1 per cent compared with the first quarter last year.
Weaker sales to retailers in the U.S. and China drove Puma's wholesale business – its main sales driver – down by 3.6 per cent.
Puma is in a period of limbo, having named former Adidas sales chief Arthur Hoeld its new CEO last month to turn performance around. Arne Freundt stepped down on April 11, and the board is leading the company until July 1 when Hoeld takes over.
Puma stuck to its 2025 outlook for 'low-to mid-single-digit' sales growth, but said that excludes any impact from U.S. tariffs.
READ SOURCE
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Liverpool break SEVEN year record to announce new signing
Liverpool have created a lot of history on the pitch over the last decade under Jurgen Klopp and Arne Slot, but there are still new milestones being reached year after year off the pitch. This summer specifically, the transfer market spending has been extraordinary. Previously, the Reds hadn't ever spent more than £200m in a window, now we're at £300m and looking at spending more. Shop the LFC Store 🚨2025/26 LFC x adidas range🚨 LFC x adidas Shop the home range today! LFC x adidas Shop the goalkeeper range today LFC x adidas Shop the new adidas range today! Furthermore, the sales has been just as mind-boggling, helping to reduce Liverpool's net spend to below £100m now, which is astonishing when you consider the standard of each of our new signings. 🔴 In Giovanni Leoni, a young 18-year-old Italian defender, the Reds have their own little piece of history. Leoni announcement breaks new ground Just through signing Leoni, the club created history as he was the first centre-back to join since Ibrahima Konate in 2021 - the fans' four-year wait for a new partner for Virgil Van Dijk finally ended. He's incredibly talented and his £30m price tag should tell you everything you need to know about what the recruitment department think of him. The club's approach is mostly data-based nowadays. At 6ft. 4in, he's a towering figure to have in the team and his six-year contract suggests that he will have a huge role to play over the next few years, especially since he's not going straight out on loan. But on Friday evening, just a few hours prior to Liverpool's first Premier League game of the season, the club announced his signing to confirm everything and he went on to create even more history. Player transfer announcement's at Anfield rarely happen. The last time was Virgil Van Dijk in 2018 when the Reds played Leicester City and the Dutchman wore an all-black suit for the occasion. As such, Leoni's appearance at Anfield on Friday for the Bournemouth game broke that seven-year record, and it gave the young Italian a chance to see up close just how Arne Slot's team operates. He will add important depth to the squad when he joins training next week and hopefully, he'll get his first taste of playing in front of the fans in a few games time when he's up to speed with the players. **🔴 **Shop the LFC 2025/26 adidas home range 🔴
Hypebeast
3 hours ago
- Hypebeast
The Slow Death of the Contemporary Art Gallery
The contemporary art gallery as we know it is dying. In cities like New York and Los Angeles, dedicated spaces that once buzzed with foot traffic and formal openings are now struggling with rising rents and changing expectations. The old model, where a gallery does everything for its artists, feels like it's falling apart. Big gallery chains, the ones built on endless art fairs, multiple cities and huge rosters of artists, are losing their grip. Last month, Tim Blum announced he would close his Blum & Poe galleries in L.A. and Tokyo and even stop plans for a new one in Tribeca. He was blunt about the reason: 'This is not about the market. This is about the system,'he told ARTnews, pointing out that collectors have more power than ever to negotiate. His decision echoes a wider feeling across the industry with many giving up on the idea of building giant gallery empires. You can see this shift happening at major events. The latestArt Baselconfirmed that galleries are showing more mid-priced work, not just the massive, ultra-expensive pieces they once counted on. A recentreport from Art Basel and UBSshowed that while the overall art market shrank last year, the number of actual sales went up. It's a clear signal that the business is no longer just about a small group of big spenders, it's now about reaching a wider audience at lower price points. 'The old model was built on scarcity and prestige. The new one runs on access and attention.' A significant force behind this change is the shifting demand for different types of art. The once-dominant 'blue-chip' artists, masters whose work commanded staggering prices, are no longer the only game in town. Collectors are increasingly turning their attention to 'red-chip' artists, a new class of talents whose value is built on viral hype and cultural relevance rather than institutional endorsement. These artists are attractive for two main reasons: their work is often more accessible and affordable, and it brings fresh, diverse cultural perspectives that feel relevant and exciting to a global audience. This hunger for new voices and unconventional methods is reshaping the market. A key example isOlaolu Slawn, a London-based artist who sold out his solo show,I present to you, Slawn, at the Saatchi Yates gallery in 2024 by creating and selling 1,000 individual, more accessible pieces, an approach that challenges the fine art world's focus on scarcity and prestige. A separate but related trend sees celebrities entering the art market with their own work, often commanding high prices based on their fame. Actor Adrien Brody is a notable example. His art, which he described is about celebrating the little nuances in life has sold for significant amounts, as per a convo withInterview Magazine. For instance, a painting he created of Marilyn Monroe was sold at a Cannes gala auction for $425,000 USD, illustrating how star power can directly translate into commercial value. However, his work has drawn sharp criticism from the industry, with critics often labeling it as kitschy and derivative. One critic writing forARTnewsdescribed his work as having a 'faux naïve aesthetic' and 'mediocre production value,' while others have accused him of cheaply appropriating the styles of Jean-Michel Basquiat and Andy Warhol. As the old guard shrinks, smaller galleries are finding new ways to thrive. In New York,Tiwa Galleryshows self-taught artists in a relaxed space, rejecting flashy Landddcombines Latin American crafts with immersive events. In L.A.,Marta galleryblends art and design right into everyday life. These new spaces care more about quiet, genuine connection than putting on a spectacle. Retail is also becoming a new kind of gallery. Stores like South Korea's Gentle Monster and London's Dover Street Market are blurring the lines between art and commerce, transforming shopping into an immersive cultural experience. Gentle Monster's stores are famous for their fantastical, ever-changing installations, from surreal kinetic sculptures to robotic figures that draw in visitors who are just as interested in the art as they are in the eyewear. Dover Street Market, founded by Comme des Garçons's Rei Kawakubo, is a 'beautiful chaos' where each brand and artist is given a dedicated space to create a unique installation, turning the store into a constantly evolving exhibition. By blending high-end retail with cutting-edge art and design these spaces offer a new kind of public access to creativity, making the gallery experience a part of a commercial transaction rather than a separate cultural outing. 'If your space is fueled by DJs and cocktails, maybe it isn't really a gallery anymore.' It's clear that going to a gallery is no longer the only way to see or buy art. Today, buyers can just scroll on their phones and purchase work directly from studios or social media. This instant access has replaced the slow dance of white-cube shows and champagne previews. Some galleries are trying to keep up, creating online art drops and hosting pop-ups in different retail spaces. But others are pushing back, as one veteran gallerist puts it: if your space is fueled by DJs and cocktails, maybe it isn't really a gallery anymore. Art isn't disappearing. It's just moving, becoming more accessible and less tied to one physical location. The old model was built on scarcity and prestige. The new one runs on access and attention. The question isn't whether galleries will survive, but which ones can change fast enough to matter.
Time Business News
7 hours ago
- Time Business News
Next-Generation Approaches to Hematologic Malignancies
Hematologic malignancies are cancer that affect blood, bone marrow, and lymphatic systems including leukemia, lymphoma and multiple myeloma. These cancers disrupt normal blood cell production and immune function. The growth of the hematologic malignancy market is inspired by increasing the prevalence of global cancer, increasing target remedies and immunotherapy, progression in clinical technologies and expanding research in individual medicine. Additionally, increasing awareness, better healthcare infrastructure, and oncology contribute to more investment market expansion in drug development. Key Growth Drivers and Opportunities Increasing the Prevalence of Global Cancer: The increasing global spread of cancer greatly enhances the growth of the market of hematologic malignancies, as blood -related cancer, such as leukemia, lymphoma and multiple myeloma, become a large part of cancer worldwide. As more individuals are affected by these conditions, there is an increasing demand for accurate diagnosis, advanced treatment options and long -term disease management solutions. In cases, this increase encourages drug companies and research institutes to invest in innovative remedies such as targeted treatment, immunotherapy and CAR-T cell therapy. Additionally, high cancer phenomena motivate governments and healthcare systems to increase screening programs and to reach oncology. Challenges Hematologic malignancies markets face several borders, including high cost of advanced treatments such as car-T cell treatment and targeted drugs, which can restrict access to patients in low- and moderate-income areas. Complex regulatory approval, long clinical testing procedures, and severe side effects or ability to resist also face significant challenges. Additionally, limited availability of specialized clinical equipment and lack of efficient health care professionals in some fields obstruct timely and accurate diagnosis, overall treatment affects results and slows down market development. Innovation and Expansion Kyowa Kirin and Kura Oncology Collaborate to Create Ziftomenib for Acute Leukemias In November 2024, in order to develop and market ziftomenib, Kura's selective oral menin inhibitor, which is being researched for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies, Kura Oncology, Inc. and Kyowa Kirin Co., Ltd. announced they have formed a global strategic partnership. Kura will get USD 330 million up front as part of the deal, and it anticipates receiving up to USD 420 million in near-term milestone payments, including one when ziftomenib is introduced in the monotherapy relapsed/refractory (R/R) context. Merck Launched Phase III Trials for Novel Treatments for Blood Disorders and Cancer In January 2024, With the start of pivotal Phase III studies for four new candidates for solid tumors and hematologic malignancies, Merck's strong oncology and hematology portfolio is progressing. Essential thrombocythemia (ET), small lymphocytic lymphoma (SLL), chronic lymphocytic leukemia (CLL), non-small cell lung cancer (NSCLC), some patients with endometrial carcinoma who have already received treatment, and metastatic castration-resistant prostate cancer (mCRPC) are among the conditions for which the company announced active enrollment for investigational medications. The firm is committed to ongoing research to broaden our portfolio of oncology treatments in order to continue addressing unmet needs in cancer care. The company has a rich history of transforming groundbreaking science into medicines that save and enhance lives worldwide. Inventive Sparks, Expanding Markets The key players operating the hematologic malignancies market includes, Johnson & Johnson Services Inc., Pfizer Inc., Novartis AG, AbbVie Inc., GlaxoSmithKline PLC., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Inc., Celgene Corporation, F. Hoffman-La Roche Ltd., Takeda Pharmaceutical Company Limited., and others. About Author: Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business. TIME BUSINESS NEWS
